疑难病杂志
疑難病雜誌
의난병잡지
JOURNAL OF DIFFICULT AND COMPLICATED CASES
2014年
4期
403-407
,共5页
万埝%夏豪%刘小熊%梅阳%唐东梁
萬埝%夏豪%劉小熊%梅暘%唐東樑
만념%하호%류소웅%매양%당동량
瑞舒伐他汀%阿托伐他汀%冠状动脉粥样硬化性心脏病%Meta分析
瑞舒伐他汀%阿託伐他汀%冠狀動脈粥樣硬化性心髒病%Meta分析
서서벌타정%아탁벌타정%관상동맥죽양경화성심장병%Meta분석
Rosuvastatin%Atorvastatin%Coronary heart disease%Meta-Analysis
目的:系统性评价瑞舒伐他汀(RSV)与阿托伐他汀(ATV)治疗冠状动脉粥样硬化性心脏病血脂的疗效与安全性。方法计算机检索PUBMED、VIP、中国知网、万方数据库关于RSV与ATV治疗冠心病的疗效与安全性的随机对照试验( RCT),同时追索纳入文献的参考文献。检索时限为2003-2013年。根据Jadad评分对纳入文献的质量进行严格评价和资料提取,对符合质量标准的RCT进行Meta分析。统计学分析采用RevMan59.0.25软件。结果共纳入10项RCT。 Meta分析结果显示:(1) LDL-C变化:RSV与ATV相比,差异无统计学意义( MD=-3.99,95%CI -9.34~1.37, P >0.05);(2)HDL-C变化:RSV与ATV相比,差异有统计学意义(MD=1.80,95%CI 1.74~1.86, P <0.01);(3)TG变化:RSV与ATV相比,差异无统计学意义(MD=9.31,95%CI -3.74~22.37, P >0.05);(4)TC变化:RSV与ATV相比,差异无统计学意义(MD=-1.21,95%CI -12.39~9.95, P >0.05);(5)不良事件(AE)发生率:RSV与ATV相比,差异无统计学意义(OR=1.02,95%CI 0.80~1.29, P >0.05)。结论与阿托伐他汀相比,瑞舒伐他汀在改善冠心病患者LDL-C、TG、TC的疗效和AE发生率方面无优越性。
目的:繫統性評價瑞舒伐他汀(RSV)與阿託伐他汀(ATV)治療冠狀動脈粥樣硬化性心髒病血脂的療效與安全性。方法計算機檢索PUBMED、VIP、中國知網、萬方數據庫關于RSV與ATV治療冠心病的療效與安全性的隨機對照試驗( RCT),同時追索納入文獻的參攷文獻。檢索時限為2003-2013年。根據Jadad評分對納入文獻的質量進行嚴格評價和資料提取,對符閤質量標準的RCT進行Meta分析。統計學分析採用RevMan59.0.25軟件。結果共納入10項RCT。 Meta分析結果顯示:(1) LDL-C變化:RSV與ATV相比,差異無統計學意義( MD=-3.99,95%CI -9.34~1.37, P >0.05);(2)HDL-C變化:RSV與ATV相比,差異有統計學意義(MD=1.80,95%CI 1.74~1.86, P <0.01);(3)TG變化:RSV與ATV相比,差異無統計學意義(MD=9.31,95%CI -3.74~22.37, P >0.05);(4)TC變化:RSV與ATV相比,差異無統計學意義(MD=-1.21,95%CI -12.39~9.95, P >0.05);(5)不良事件(AE)髮生率:RSV與ATV相比,差異無統計學意義(OR=1.02,95%CI 0.80~1.29, P >0.05)。結論與阿託伐他汀相比,瑞舒伐他汀在改善冠心病患者LDL-C、TG、TC的療效和AE髮生率方麵無優越性。
목적:계통성평개서서벌타정(RSV)여아탁벌타정(ATV)치료관상동맥죽양경화성심장병혈지적료효여안전성。방법계산궤검색PUBMED、VIP、중국지망、만방수거고관우RSV여ATV치료관심병적료효여안전성적수궤대조시험( RCT),동시추색납입문헌적삼고문헌。검색시한위2003-2013년。근거Jadad평분대납입문헌적질량진행엄격평개화자료제취,대부합질량표준적RCT진행Meta분석。통계학분석채용RevMan59.0.25연건。결과공납입10항RCT。 Meta분석결과현시:(1) LDL-C변화:RSV여ATV상비,차이무통계학의의( MD=-3.99,95%CI -9.34~1.37, P >0.05);(2)HDL-C변화:RSV여ATV상비,차이유통계학의의(MD=1.80,95%CI 1.74~1.86, P <0.01);(3)TG변화:RSV여ATV상비,차이무통계학의의(MD=9.31,95%CI -3.74~22.37, P >0.05);(4)TC변화:RSV여ATV상비,차이무통계학의의(MD=-1.21,95%CI -12.39~9.95, P >0.05);(5)불량사건(AE)발생솔:RSV여ATV상비,차이무통계학의의(OR=1.02,95%CI 0.80~1.29, P >0.05)。결론여아탁벌타정상비,서서벌타정재개선관심병환자LDL-C、TG、TC적료효화AE발생솔방면무우월성。
Objective To systematic evaluate the efficacy and safety of rosuvastatin ( RSV) and atorvastatin ( ATV) for treatment of coronary atherosclerotic heart disease lipid .Methods The PUBMED, VIP, CNKI, Wanfang data were col-lected and randomized controlled trials ( RCT) of efficacy and safety of RSV and ATV in treatment of coronary heart disease , while recourse included literature references .Retrieval time was from 2003 to 2013 .Jadad score were used for literature evalu-ation and information extraction .Statistical analysis was performed using RevMan 5.0.25 software.Results A total of 10 trials were included.Meta-analysis demonstrated that :(1) LDL-C:RSV compared with the ATV, the difference was not statisti-cally significant (MD=-3.99, 95%CI -9.34 -1.37, P >0.05); (2) HDL-C: RSV compared with the ATV, the difference was statistically significant (MD=1.80, 95% CI 1.74 -1.86, P <0.01); (3) TG: RSV compared with the ATV, the difference was not statistically significant (MD=9.31, 95% CI -3.74 -22.37, P >0.05); (4) TC: RSV compared with the ATV, the difference was not statistically significant (MD=-1.21, 95%CI -12.39-9.95, P >0.05);(5) Adverse event (AE) rates: RSV compared with the ATV, the difference was not statistically significant (OR=1.02, 95%CI 0.80-1.29, P >0.05).Conclusion Compared with atorvastatin, rosuvastatin reveals no advantage in improving LDL-C, TG, TC and AE incidence in patients with coronary artery disease .